Associated organisations of the MHA
Midlands Health Innovation
Midlands Health Innovation is a research and innovation partnership that coordinates and combines the collective excellence of 7 Midlands universities to deliver improved health and regional growth. Driving disruptive translational interventions and influencing nationally, MHI draws together a critical mass of innovative regional stakeholders to impact national and global health challenges using local training strengths, expertise, networks, best practice and facilities.
As the Health and Medicine branch of Midlands Innovation, we are united in our determination that:
Individually we are strong, with world-class research, creativity and skills development.
Together we are stronger, playing a significant role in stimulating economic growth across the region and beyond.
As a collaborative translational engine for healthcare, Midlands Health Innovation represents:
A critical mass of regional research and innovation activity
A platform for delivering disruptive interventions
A ‘Team Science’ community of good practice, technical expertise and peer support
An ability to rapidly coordinate potential synergies and delivery of joint innovation
A partnership forum promoting Midlands innovation in research, policy and practice
A Joint Strategy
The aim of this initiative is to position the cutting-edge Medical and Health-based innovations and research produced across the Midlands at the forefront of the UK. We are also striving to create more large-scale collaborative activities across the partnership and with others.
This will be achieved by delivering against the following objectives:
To provide co-ordination for the generation of research intensive applications and initiatives which link MHI Universities. These will often involve linking with industry, the NHS and/or local government
To facilitate sharing of resources between MHI Universities, with the aim of furthering collaboration and expanding capabilities
To increasing research and collaboration with Midlands NHS Trusts to co-ordinate patient-based research facilities across the Midlands
To respond as a united voice to consultations and funding opportunities which are targeted at the Midlands region as a whole
SCALE IN RESEARCH
High quality translational research and clinical trials infrastructure, hosting multiple national centres of research excellence, 3 BRCs and 4 CRFs. >£260M health research p.a.
SCALE IN HEALTHCARE
50 NHS Trusts, supporting a population of ~11million (1/6 UK) and 27% of the country’s NHS Sustainability and Transformation Partnerships.
SCALE IN SKILLS
Our Medical Schools train 20% of the UK’s medical professionals, within a region where 38% are employed within highly skilled, knowledge intensive sectors.
SCALE IN INDUSTRY
MHI partners deliver >£130M of Business and Community engagement p.a. The Midlands region is also in the UK’s top 3 for Life Sciences employment (>30,000 jobs).
The ATTC project aims to develop robust systems for the routine delivery of ATMPs as a standard of care throughout the NHS in the United Kingdom.
Over the last five years, new cell and gene therapies have been developed to treat some cancers and inherited diseases. These advanced therapies are different from existing treatments in two important ways: they are designed to restore normal function, sometimes offering cures where unmet medical need exists and they require new ways of working by the NHS.
The ATTC Network Programme is a world-first, UK system of Advanced Therapy Treatment Centres (ATTC) operating within the NHS framework and coordinated by the Cell and Gene Therapy Catapult to address the unique and complex challenges of bringing pioneering advanced therapy medicinal products (ATMPs) to patients. The centres include:
Innovate Manchester Advanced Therapy Centre Hub (iMATCH),
Midlands-Wales Advanced Therapy Treatment Centre (MW-ATTC, comprising Birmingham, Wales and Nottingham) and
Northern Alliance Advanced Therapies Treatment Centre (NAATTC, comprising Scotland, Newcastle and Leeds)
The network is initially supported by the Industrial Challenge Strategy Fund with the aim to develop first-of-a-kind technologies for the manufacture of innovative medicines across areas including blindness, cancer, heart failure, liver disease, neurological conditions and rare paediatric diseases.
As a goal of this three year project, the ATTCs are working together with industry partners and the public sector to develop the necessary processes, skilled staff and infrastructure at scale as more treatments move from clinical trial to marketed products.
The CGT Catapult is playing a central coordination role for the network and provide support to manufacturing, supply chain logistics, regulatory affairs, clinical trial capability, R&D support and upskilling via specialist training and development.